Compare PFLT & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFLT | CADL |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 805.6M | 357.4M |
| IPO Year | 2010 | 2021 |
| Metric | PFLT | CADL |
|---|---|---|
| Price | $8.37 | $4.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $10.67 | ★ $19.00 |
| AVG Volume (30 Days) | 960.9K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 14.70% | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | $8.16 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.68 | $4.34 |
| 52 Week High | $10.88 | $7.24 |
| Indicator | PFLT | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 55.27 | 46.89 |
| Support Level | $7.92 | $4.56 |
| Resistance Level | $9.46 | $5.42 |
| Average True Range (ATR) | 0.23 | 0.24 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 76.06 | 60.78 |
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.